ArticleAnnals of surgical oncology2026
Association of Adjuvant Immunotherapy with Improved Survival for Stage II-III Esophageal Cancer: 4-Year National Perspective.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe recent ground-breaking CheckMate 577 trial demonstrated that patients with esophageal cancer (EC) who underwent neoadjuvant chemoradiation and surgery followed by adjuvant immunotherapy experienced significantly improved survival. However, nationwide utilization of adjuvant immunotherapy remains unknown, as does the impact of such treatment on overall survival outside of the clinical trial setting. PATIENTS AND
methodsWe identified all patients ≥ 18 years diagnosed with clinical stage II-III EC from January 2018 to December 2022 within the National Cancer Database. Only patients who underwent neoadjuvant chemoradiation and definitive esophagectomy with complete resection, found to have residual pathologic disease, were included. Patients were stratified by receipt of adjuvant immunotherapy into immunotherapy or no-immunotherapy cohorts.
resultsOf 1367 patients, 342 (25%) received adjuvant immunotherapy. Utilization of immunotherapy in the adjuvant setting dramatically increased from 3% in 2018 to 50% in 2022 (P < 0.001). Following comprehensive risk adjustment, receipt of adjuvant immunotherapy was associated with significantly reduced mortality hazard at 1 (HR 0.25, CI 0.15-0.41) and 3 (HR 0.60, CI 0.44-0.81) years. Upon restricted mean survival time (RMST) analysis, patients who received adjuvant immunotherapy were found to experience 4.61 additional months of survival time over 3 years of follow-up (ΔRMST 4.61 months, CI 1.94-7.28).
conclusionsUtilization of adjuvant immunotherapy among patients with locally advanced residual disease following multimodal treatment has dramatically increased since the Checkmate 577 trial. In this national study, patients who received adjuvant immunotherapy experienced ~5 months of survival benefit. Yet, with such an incremental impact on survival, additional studies are needed to further optimize the multimodal perioperative treatment of patients with EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.